Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Journal of Medicinal Chemistry|July 21, 2006
Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agentsPascal Furet, Guido Bold, Thomas Meyer, et al.European Journal of Medicinal Chemistry|February 28, 2004
Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptorChristoph Liechti, Urs Séquin, Guido Bold, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searchingPascal Furet, Guido Bold, Francesco Hofmann, et al.The American Journal of Pathology|June 7, 2008
Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitorCornelia Halin, Hermann Fahrngruber, Josef G Meingassner, et al.Bioorganic & Medicinal Chemistry Letters|April 8, 2014
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interactionAndrea Vaupel, Guido Bold, Alain De Pover, et al.Genes & Cancer|July 23, 2011
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity ComparisonEllen Weisberg, Johannes Roesel, Pascal Furet, et al.International Journal of Oncology|October 24, 2014
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)Andreas K A Gaumann, Hannes C A Drexler, Sven A Lang, et al.Biochimica Et Biophysica Acta|March 17, 2004
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesisPaul William Manley, Guido Bold, Josef Brüggen, et al.Angewandte Chemie (International Ed. in English)|October 13, 2015
A General Strategy for Targeting Drugs to BoneWolfgang Jahnke, Guido Bold, Andreas L Marzinzik, et al.Journal of Medicinal Chemistry|December 13, 2002
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitorsPaul W Manley, Pascal Furet, Guido Bold, et al.Pageof 2